**AMENDMENTS TO THE CLAIMS** 

Docket No.: C2432.0068

1(Original). Pharmaceutical composition for the treatment of constipation by rectal

administration comprising a polar lipid component, a polyvalent alcohol component,

water, and optionally an oily triglyceride.

2(Currently amended). The composition of claim 1, wherein the oily triglyceride

component is present and is a fraction of natural triglyceride.

3(Original). The composition of claim 2, wherein the oily triglyceride component

comprises fractionated oat oil.

4(Currently amended). The composition of any of claims 1-3 claim 1, wherein the polar

lipid component comprises galactolipid.

5(Original). The composition of claim 4, wherein the galactolipid comprises

digalactosyldiacylglycerol.

6(Currently amended). The composition of any of claims 1-5 claim 1, wherein the

polyvalent alcohol component is selected from the group consisting of glycerol,

propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, butylene-1,4-diol,

pentylene-1,5-diol, hexylene-1,6-diol, macrogol, and their mixtures thereof.

7(Currently amended). The composition of claim 6, wherein the polyvalent alcohol

component comprises is glycerol or propylene glycol.

8(Canceled).

3

DOCSNY-207965v01

 $Application \ No. \ National \ Phase \ of \ PCT/SE2005/000139$ 

Amendment dated August 3, 2006

First Preliminary Amendment

9(Currently amended). The composition of <del>any of claims 1-8</del> <u>claim 1</u>, comprising from 0

Docket No.: C2432.0068

per cent to 30 per cent of oily triglyceride and from 0.5 to 30 per cent of polar lipid

component.

10(Currently amended). The composition of any of claims 1-9 claim 1 of a creamy

consistence, comprising from 5 to 30 per cent of oily triglyceride.

11(Currently amended). The composition of any of claims 1-9 claim 1 of a gellous or

viscous consistence, comprising from 5 per cent to 30 per cent of polar lipid component,

with the provisio that it is free from oily triglyceride.

12(Original). The composition of claim 11, comprising from 8 per cent to 25 per cent of

polar lipid component.

13(Canceled).

14(Currently amended). The composition of <del>any of claims 11–13</del> <u>claim 11</u>, comprising

from 5 per cent to 75 per cent of polyvalent alcohol component.

15(Currently amended). The composition of any-of-claims 11-13 claim 11, comprising

from 8 per cent to 70 per cent of polyvalent alcohol component and from 10 per cent to

20 per cent of polar lipid component.

16 (Canceled).

4

DOCSNY-207965v01

17(Original). The composition of claim 11, essentially consisting of from 8 to 25 per cent

Docket No.: C2432.0068

of galactolipid, from 8 to 75 per cent of glycerol, and from 20 to 75 per cent of water,

with the proviso that said components add up to 100 per cent.

18(Currently amended). The composition of <del>any of claims 1-17</del> from 10 per cent to 20

per cent of polar lipid component comprising a pharmacologically active agent.

19(Currently amended). The composition of claim 18, wherein the pharmacologically

active agent is selected from the group consisting of sulphasalazine, sodium

aminosalicylate, diazepam, chlorpromazine, tramadol, morphine, domperidone,

piroxicam, paracetamol, indomethacin, diclofenac, naproxen, metronidazole,

antibiotics, antimycotics, and local anaesthetics for use in hemorrhoid treatment local

anaesthetics such as lidocaine.

20(Canceled).

21(Currently amended). The composition of any of claims 1-20 claim 1 having a

dynamic viscosity at 20°C of at least 2.5°10<sup>-3</sup> Ns/m<sup>2</sup>.

22(Currently amended). The composition of any of claims 1-20 claim 21 having a

dynamic viscosity at 20°C of at least about 5 10<sup>-3</sup> Ns/m<sup>2</sup>.

23. The composition of any of claims 1-20 claim 21 having a dynamic viscosity at 20°C

of at least about 9.10-3 Ns/m<sup>2</sup>.

5

Application No. National Phase of PCT/SE2005/000139 Amendment dated August 3, 2006

First Preliminary Amendment

24(Currently amended). Compressible device filled with a single dose of the

Docket No.: C2432.0068

composition of any of claims 1-23 provided claim 1 and having with a sealed

mouthpiece adapted for rectal administration.

25(Currently amended). The device of claim 24 in form of a syringe or soft polymer

<u>container</u>.

26(Canceled).

27(Currently amended). The device of any of claims 24-26 claim 24, wherein the single

dose has a volume of from 5 to 50 ml.

28(Currently amended). A method of treating constipation, comprising rectal

administration of a constipation-dissolving amount of the composition of any of claims

1-23 <u>claim 1</u> to a person suffering from constipation.

29 – 32 (Canceled).

6